DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Multiple Sclerosis – Access & Reimbursement – Access & Reimbursement – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market continues to evolve as each new approved disease-modifying therapy (DMT) further expands treatment choice. The most recent launches have entered…
Parkinson’s Disease – Unmet Need – Unmet Need – Levodopa-Induced Dyskinesia (US/EU)
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…
Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (EU5)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most…
Epilepsy – Current Treatment – Current Treatment: Physician Insights – Lennox-Gastaut Syndrome (US)
Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delays or regression, multiple seizure types, and electroencephalographic abnormalities…
Traumatic Brain Injury – Epidemiology – Epidemiology – Traumatic Brain Injury – Mature markets
Clarivate Epidemiology’s coverage of traumatic brain injury comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
